Inclusion body myositis, viral infections, and TDP-43: a narrative review.
Inclusion body myositis
Interferon gamma
Long COVID
Myositis triggers
TDP-43
Journal
Clinical and experimental medicine
ISSN: 1591-9528
Titre abrégé: Clin Exp Med
Pays: Italy
ID NLM: 100973405
Informations de publication
Date de publication:
02 May 2024
02 May 2024
Historique:
received:
21
03
2024
accepted:
15
04
2024
medline:
2
5
2024
pubmed:
2
5
2024
entrez:
1
5
2024
Statut:
epublish
Résumé
The ubiquitous RNA-processing molecule TDP-43 is involved in neuromuscular diseases such as inclusion body myositis, a late-onset acquired inflammatory myopathy. TDP-43 solubility and function are disrupted in certain viral infections. Certain viruses, high viremia, co-infections, reactivation of latent viruses, and post-acute expansion of cytotoxic T cells may all contribute to inclusion body myositis, mainly in an age-shaped immune landscape. The virally induced senescent, interferon gamma-producing cytotoxic CD8+ T cells with increased inflammatory, and cytotoxic features are involved in the occurrence of inclusion body myositis in most such cases, in a genetically predisposed host. We discuss the putative mechanisms linking inclusion body myositis, TDP-43, and viral infections untangling the links between viruses, interferon, and neuromuscular degeneration could shed a light on the pathogenesis of the inclusion body myositis and other TDP-43-related neuromuscular diseases, with possible therapeutic implications.
Identifiants
pubmed: 38693436
doi: 10.1007/s10238-024-01353-9
pii: 10.1007/s10238-024-01353-9
doi:
Substances chimiques
DNA-Binding Proteins
0
TARDBP protein, human
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
91Informations de copyright
© 2024. The Author(s).
Références
Greenberg SA. Inclusion body myositis: clinical features and pathogenesis. Nat Rev Rheumatol. 2019;15(5):257–72. https://doi.org/10.1038/s41584-019-0186-x .
doi: 10.1038/s41584-019-0186-x
pubmed: 30837708
McLeish E, Slater N, Sooda A, Wilson A, Coudert JD, Lloyd TE, Needham M. Inclusion body myositis: the interplay between ageing, muscle degeneration and autoimmunity. Best Pract Res Clin Rheumatol. 2022;36(2):101761. https://doi.org/10.1016/j.berh.2022.101761 .
doi: 10.1016/j.berh.2022.101761
pubmed: 35760741
Lundberg IE, de Visser M, Werth VP. Classification of myositis. Nat Rev Rheumatol. 2018;14(5):269–78. https://doi.org/10.1038/nrrheum.2018.41 .
doi: 10.1038/nrrheum.2018.41
pubmed: 29651121
Nelke C, Kleefeld F, Preusse C, Ruck T, Stenzel W. Inclusion body myositis and associated diseases: an argument for shared immune pathologies. Acta Neuropathol Commun. 2022;10(1):84. https://doi.org/10.1186/s40478-022-01389-6 .
doi: 10.1186/s40478-022-01389-6
pubmed: 35659120
pmcid: 9164382
Snedden AM, Kellett KAB, Lilleker JB, Hooper NM, Chinoy H. The role of protein aggregation in the pathogenesis of inclusion body myositis. Clin Exp Rheumatol. 2022;40(2):414–24. https://doi.org/10.55563/clinexprheumatol/pp0oso .
doi: 10.55563/clinexprheumatol/pp0oso
pubmed: 35225225
Versluys L, Ervilha Pereira P, Schuermans N, De Paepe B, De Bleecker JL, Bogaert E, Dermaut B. Expanding the TDP-43 proteinopathy pathway from neurons to muscle: physiological and pathophysiological functions. Front Neurosci. 2022;16:815765. https://doi.org/10.3389/fnins.2022.815765 .
doi: 10.3389/fnins.2022.815765
pubmed: 35185458
pmcid: 8851062
Weihl CC, Temiz P, Miller SE, Watts G, Smith C, Forman M, Hanson PI, et al. TDP-43 accumulation in inclusion body myopathy muscle suggests a common pathogenic mechanism with frontotemporal dementia. J Neurol Neurosurg Psychiatry. 2008;79(10):1186–9. https://doi.org/10.1136/jnnp.2007.131334 .
doi: 10.1136/jnnp.2007.131334
pubmed: 18796596
Šušnjar U, Škrabar N, Brown AL, Abbassi Y, Phatnani H, NYGC ALS Consortium, Cortese A, et al. Cell environment shapes TDP-43 function with implications in neuronal and muscle disease. Commun Biol. 2022;5(1):314. https://doi.org/10.1038/s42003-022-03253-8 .
Buratti E. TDP-43 post-translational modifications in health and disease. Expert Opin Ther Targets. 2018;22(3):279–93. https://doi.org/10.1080/14728222.2018.1439923 .
doi: 10.1080/14728222.2018.1439923
pubmed: 29431050
Britson KA, Ling JP, Braunstein KE, Montagne JM, Kastenschmidt JM, Wilson A, Ikenaga C, et al. Loss of TDP-43 function and rimmed vacuoles persist after T cell depletion in a xenograft model of sporadic inclusion body myositis. Sci Transl Med. 2022;14(628):eabi9196. https://doi.org/10.1126/scitranslmed.abi9196 .
doi: 10.1126/scitranslmed.abi9196
pubmed: 35044790
pmcid: 9118725
Salajegheh M, Pinkus JL, Taylor JP, Amato AA, Nazareno R, Baloh RH, Greenberg SA. Sarcoplasmic redistribution of nuclear TDP-43 in inclusion body myositis. Muscle Nerve. 2009;40(1):19–31. https://doi.org/10.1002/mus.21386 .
doi: 10.1002/mus.21386
pubmed: 19533646
pmcid: 2700211
Rahic Z, Buratti E, Cappelli S. Reviewing the potential links between viral infections and TDP-43 proteinopathies. Int J Mol Sci. 2023;24(2):1581. https://doi.org/10.3390/ijms24021581 .
doi: 10.3390/ijms24021581
pubmed: 36675095
pmcid: 9867397
Dunker W, Ye X, Zhao Y, Liu L, Richardson A, Karijolich J. TDP-43 prevents endogenous RNAs from triggering a lethal RIG-I-dependent interferon response. Cell Rep. 2021;35(2):108976. https://doi.org/10.1016/j.celrep.2021.108976 .
doi: 10.1016/j.celrep.2021.108976
pubmed: 33852834
pmcid: 8109599
Liu W, Wang Z, Liu L, Yang Z, Liu S, Ma Z, Liu Y, et al. LncRNA Malat1 inhibition of TDP43 cleavage suppresses IRF3-initiated antiviral innate immunity. Proc Natl Acad Sci U S A. 2020;117(38):23695–706. https://doi.org/10.1073/pnas.2003932117 .
doi: 10.1073/pnas.2003932117
pubmed: 32907941
pmcid: 7519350
Ylä-Anttila P. Autophagy receptors as viral targets. Cell Mol Biol Lett. 2021;26(1):29. https://doi.org/10.1186/s11658-021-00272-x .
doi: 10.1186/s11658-021-00272-x
pubmed: 34167456
pmcid: 8222950
Askanas V, Engel WK. Inclusion-body myositis: newest concepts of pathogenesis and relation to aging and Alzheimer disease. J Neuropathol Exp Neurol. 2001;60(1):1–14. https://doi.org/10.1093/jnen/60.1.1 .
doi: 10.1093/jnen/60.1.1
pubmed: 11202170
Dubowsky M, Theunissen F, Carr JM, Rogers ML. The molecular link between TDP-43, endogenous retroviruses and inflammatory neurodegeneration in amyotrophic lateral sclerosis: a potential target for Triumeq, an antiretroviral therapy. Mol Neurobiol. 2023;60(11):6330–45. https://doi.org/10.1007/s12035-023-03472-y .
doi: 10.1007/s12035-023-03472-y
pubmed: 37450244
pmcid: 10533598
Morosetti R, Broccolini A, Sancricca C, Gliubizzi C, Gidaro T, Tonali PA, Ricci E, Mirabella M. Increased aging in primary muscle cultures of sporadic inclusion-body myositis. Neurobiol Aging. 2010;31(7):1205–14. https://doi.org/10.1016/j.neurobiolaging.2008.08.011 .
doi: 10.1016/j.neurobiolaging.2008.08.011
pubmed: 18823681
Germain MA, Chatel-Chaix L, Gagné B, Bonneil É, Thibault P, Pradezynski F, de Chassey B, et al. Elucidating novel hepatitis C virus-host interactions using combined mass spectrometry and functional genomics approaches. Mol Cell Proteomics. 2014;13(1):184–203. https://doi.org/10.1074/mcp.M113.030155 .
doi: 10.1074/mcp.M113.030155
pubmed: 24169621
Lloyd TE, Pinal-Fernandez I, Michelle EH, Christopher-Stine L, Pak K, Sacktor N, Mammen AL. Overlapping features of polymyositis and inclusion body myositis in HIV-infected patients. Neurology. 2017;88(15):1454–60. https://doi.org/10.1212/WNL.0000000000003821 .
doi: 10.1212/WNL.0000000000003821
pubmed: 28283597
pmcid: 5386438
Saldi TK, Ash PE, Wilson G, Gonzales P, Garrido-Lecca A, Roberts CM, Dostal V, et al. TDP-1, the Caenorhabditis elegans ortholog of TDP-43, limits the accumulation of double-stranded RNA. EMBO J. 2014;33(24):2947–66. https://doi.org/10.15252/embj.201488740 .
doi: 10.15252/embj.201488740
pubmed: 25391662
pmcid: 4282642
Fung G, Shi J, Deng H, Hou J, Wang C, Hong A, Zhang J, et al. Cytoplasmic translocation, aggregation, and cleavage of TDP-43 by enteroviral proteases modulate viral pathogenesis. Cell Death Differ. 2015;22(12):2087–97. https://doi.org/10.1038/cdd.2015.58 .
doi: 10.1038/cdd.2015.58
pubmed: 25976304
pmcid: 4816113
Rathore A, Iketani S, Wang P, Jia M, Sahi V, Ho DD. CRISPR-based gene knockout screens reveal deubiquitinases involved in HIV-1 latency in two Jurkat cell models. Sci Rep. 2020;10(1):5350. https://doi.org/10.1038/s41598-020-62375-3 .
doi: 10.1038/s41598-020-62375-3
pubmed: 32210344
pmcid: 7093534
Li Y, Lu S, Gu J, Xia W, Zhang S, Zhang S, Wang Y, et al. SARS-CoV-2 impairs the disassembly of stress granules and promotes ALS-associated amyloid aggregation. Protein Cell. 2022;13(8):602–14. https://doi.org/10.1007/s13238-022-00905-7 .
doi: 10.1007/s13238-022-00905-7
pubmed: 35384603
pmcid: 8983322
Xue Y, Zhang J, Ke J, Zeng L, Cheng K, Han X, Chen F, et al. LncGBP9 knockdown alleviates myocardial inflammation and apoptosis in mice with acute viral myocarditis via suppressing NF-kappaB signaling pathamianway. Inflamm Res. 2022;71(12):1559–76. https://doi.org/10.1007/s00011-022-01644-5 .
doi: 10.1007/s00011-022-01644-5
pubmed: 36301340
Chang YH, Dubnau J. Endogenous retroviruses and TDP-43 proteinopathy form a sustaining feedback driving intercellular spread of Drosophila neurodegeneration. Nat Commun. 2023;14(1):966. https://doi.org/10.1038/s41467-023-36649- .
doi: 10.1038/s41467-023-36649-
pubmed: 36810738
pmcid: 9944888
Keller CW, Schmidt J, Lunemann JD. Immune and myodegenerative pathomechanisms in inclusion body myositis. Ann Clin Transl Neurol. 2017;4(6):422–45. https://doi.org/10.1002/acn3.419 .
doi: 10.1002/acn3.419
pubmed: 28589170
pmcid: 5454400
Nishino H, Engel AG, Rima BK. Inclusion body myositis: the mumps virus hypothesis. Ann Neurol. 1989;25(3):260–4. https://doi.org/10.1002/ana.410250309 .
doi: 10.1002/ana.410250309
pubmed: 2729916
Agergaard J, Leth S, Pedersen TH, Harbo T, Blicher JU, Karlsson P, Ostergaard L, et al. Myopathic changes in patients with long-term fatigue after COVID-19. Clin Neurophysiol. 2021;132(8):1974–81. https://doi.org/10.1016/j.clinph.2021.04.009 .
doi: 10.1016/j.clinph.2021.04.009
pubmed: 34020890
pmcid: 8102077
Galeotti C, Bayry J. Autoimmune and inflammatory diseases following COVID-19. Nat Rev Rheumatol. 2020;16(8):413–4. https://doi.org/10.1038/s41584-020-0448-7 .
doi: 10.1038/s41584-020-0448-7
pubmed: 32499548
pmcid: 7271827
Nguyen TM, Kabotyanski EB, Reineke LC, Shao J, Xiong F, Lee JH, Dubrulle J, et al. The SINEB1 element in the long non-coding RNA Malat1 is necessary for TDP-43 proteostasis. Nucleic Acids Res. 2020;8(5):2621–42. https://doi.org/10.1093/nar/gkz1176 .
doi: 10.1093/nar/gkz1176
Li XL, Ezelle HJ, Hsi TY, Hassel BA. A central role for RNA in the induction and biological activities of type 1 interferons. Wiley Interdiscip Rev RNA. 2011;2(1):58–78. https://doi.org/10.1002/wrna.32 .
doi: 10.1002/wrna.32
pubmed: 21956969
Piazzi M, Bavelloni A, Cenni V, Faenza I, Blalock WL. Revisiting the role of GSK3, a modulator of innate immunity, in idiopathic inclusion body myositis. Cells. 2021;10(11):3255. https://doi.org/10.3390/cells10113255 .
doi: 10.3390/cells10113255
pubmed: 34831477
pmcid: 8625526
Sreedharan J, Neukomm LJ, Brown Jr RH, Freeman MR. Age-dependent TDP-43-mediated motor neuron degeneration requires GSK3, hat-trick, and xmas-2. Curr Biol. 2015;25(16):2130–6. https://doi.org/10.1016/j.cub.2015.06.045 .
doi: 10.1016/j.cub.2015.06.045
pubmed: 26234214
pmcid: 4546534
Liu XL, Sun DD, Zheng MT, Li XT, Niu HH, Zhang L, Zhou ZW, et al. Maraviroc promotes recovery from traumatic brain injury in mice by suppression of neuroinflammation and activation of neurotoxic reactive astrocytes. Neural Regen Res. 2023;18(1):141–9. https://doi.org/10.4103/1673-5374.344829 .
doi: 10.4103/1673-5374.344829
pubmed: 35799534
Medeiros GA, Silvério JC, Marino AP, Roffê E, Vieira V, Kroll-Palhares K, Carvalho CE, Silva AA, et al. Treatment of chronically Trypanosoma cruzi-infected mice with a CCR1/CCR5 antagonist (Met-RANTES) results in amelioration of cardiac tissue damage. Microbes Infect. 2009;11(2):264–73. https://doi.org/10.1016/j.micinf.2008.11.012 .
doi: 10.1016/j.micinf.2008.11.012
pubmed: 19100857
Webber CJ, Murphy CN, Rondón-Ortiz AN, van der Spek SJF, Kelly EX, Lampl NM, Chiesa G, et al. Human herpesvirus 8 ORF57 protein is able to reduce TDP-43 pathology: network analysis identifies interacting pathways. Hum Mol Genet. 2023;32(20):2966–80. https://doi.org/10.1093/hmg/ddad122 .
doi: 10.1093/hmg/ddad122
pubmed: 37522762
Huntley ML, Gao J, Termsarasab P, Wang L, Zeng S, Thammongkolchai T, Liu Y, et al. Association between TDP-43 and mitochondria in inclusion body myositis. Lab Invest. 2019;99(7):1041–8. https://doi.org/10.1038/s41374-019-0233-x .
doi: 10.1038/s41374-019-0233-x
pubmed: 30742062
pmcid: 6609472
Idrees D, Kumar V. SARS-CoV-2 spike protein interactions with amyloidogenic proteins: potential clues to neurodegeneration. Biochem Biophys Res Commun. 2021;554:94–8. https://doi.org/10.1016/j.bbrc.2021.03.100 .
doi: 10.1016/j.bbrc.2021.03.100
pubmed: 33789211
pmcid: 7988450
Huang K, Wang C, Vagts C, Raguveer V, Finn PW, Perkins DL. Long non-coding RNAs (lncRNAs) NEAT1 and MALAT1 are differentially expressed in severe COVID-19 patients: an integrated single-cell analysis. PLoS ONE. 2022;17(1):e0261242. https://doi.org/10.1371/journal.pone.0261242 .
doi: 10.1371/journal.pone.0261242
pubmed: 35007307
pmcid: 8746747
Menon MP, Hua KF. The long non-coding RNAs: paramount regulators of the NLRP3 inflammasome. Front Immunol. 2020;11:569524. https://doi.org/10.3389/fimmu.2020.569524 .
doi: 10.3389/fimmu.2020.569524
pubmed: 33101288
pmcid: 7546312
Hamann PD, Roux BT, Heward JA, Love S, McHugh NJ, Jones SW, Lindsay MA. Transcriptional profiling identifies differential expression of long non-coding RNAs in Jo-1 associated and inclusion body myositis. Sci Rep. 2017;7(1):8024. https://doi.org/10.1038/s41598-017-08603-9 .
doi: 10.1038/s41598-017-08603-9
pubmed: 28808260
pmcid: 5556005
Askanas V, Engel WK, Nogalska A. Inclusion body myositis: a degenerative muscle disease associated with intra-muscle fiber multi-protein aggregates, proteasome inhibition, endoplasmic reticulum stress and decreased lysosomal degradation. Brain Pathol. 2009;19(3):493–506. https://doi.org/10.1111/j.1750-3639.2009.00290.x .
doi: 10.1111/j.1750-3639.2009.00290.x
pubmed: 19563541
pmcid: 8094750
Ghannam K, Martinez-Gamboa L, Spengler L, Krause S, Smiljanovic B, Bonin M, Bhattarai S, et al. Upregulation of immunoproteasome subunits in myositis indicates active inflammation with involvement of antigen presenting cells, CD8 T-cells and IFNGamma. PLoS ONE. 2014;9(8):e104048. https://doi.org/10.1371/journal.pone.0104048 .
doi: 10.1371/journal.pone.0104048
pubmed: 25098831
pmcid: 4123911
van den Eshof BL, Medfai L, Nolfi E, Wawrzyniuk M, Sijts AJAM. The function of immunoproteasomes—an immunologists’ perspective. Cells. 2021;10(12):3360. https://doi.org/10.3390/cells10123360 .
doi: 10.3390/cells10123360
pubmed: 34943869
pmcid: 8699091
Wellington D, Yin Z, Yu Z, Heilig R, Davis S, Fischer R, Felce SL, et al. SARS-CoV-2 mutations affect antigen processing by the proteasome to alter CD8+ T cell responses. Heliyon. 2023;9(10):e20076. https://doi.org/10.1016/j.heliyon.2023.e20076 .
doi: 10.1016/j.heliyon.2023.e20076
pubmed: 37842619
pmcid: 10570596
Ferrer I, Martin B, Castano JG, Lucas JJ, Moreno D, Olive M. Proteasomal expression, induction of immunoproteasome subunits, and local MHC class I presentation in myofibrillar myopathy and inclusion body myositis. J Neuropathol Exp Neurol. 2004;63(5):484–98. https://doi.org/10.1093/jnen/63.5.484 .
doi: 10.1093/jnen/63.5.484
pubmed: 15198127
Bolko L, Jiang W, Tawara N, Landon-Cardinal O, Anquetil C, Benveniste O, Allenbach Y. The role of interferons type I, II and III in myositis: a review. Brain Pathol. 2021;31(3):e12955. https://doi.org/10.1111/bpa.12955 .
doi: 10.1111/bpa.12955
pubmed: 34043262
pmcid: 8412069
Ivanidze J, Hoffmann R, Lochmuller H, Engel AG, Hohlfeld R, Dornmair K. Inclusion body myositis: laser microdissection reveals differential up-regulation of IFN-gamma signaling cascade in attacked versus nonattacked myofibers. Am J Pathol. 2011;179(3):1347–59. https://doi.org/10.1016/j.ajpath.2011.05.055 .
doi: 10.1016/j.ajpath.2011.05.055
pubmed: 21855683
pmcid: 3157228
Ekholm L, Vosslamber S, Tjarnlund A, de Jong TD, Betteridge Z, McHugh N, Plestilova L, et al. Autoantibody specificities and type I interferon pathway activation in idiopathic inflammatory myopathies. Scand J Immunol. 2016;84(2):100–9. https://doi.org/10.1111/sji.12449 .
doi: 10.1111/sji.12449
pubmed: 27173897
Angeles A, Fung G, Luo H. Immune and non-immune functions of the immunoproteasome. Front Biosci (Landmark Ed). 2012;17(5):1904–16. https://doi.org/10.1093/jnen/60.1.1 .
doi: 10.1093/jnen/60.1.1
pubmed: 22201844
Ayaki T, Murata K, Kanazawa N, Uruha A, Ohmura K, Sugie K, Kasagi S, et al. Myositis with sarcoplasmic inclusions in Nakajo-Nishimura syndrome: a genetic inflammatory myopathy. Neuropathol Appl Neurobiol. 2020;46(6):579–87. https://doi.org/10.1111/nan.12614 .
doi: 10.1111/nan.12614
pubmed: 32144790
Pinal-Fernandez I, Casal-Dominguez M, Derfoul A, Pak K, Plotz P, Miller FW, Milisenda JC, et al. Identification of distinctive interferon gene signatures in different types of myositis. Neurology. 2019;93(12):e1193–204. https://doi.org/10.1212/WNL.0000000000008128 .
doi: 10.1212/WNL.0000000000008128
pubmed: 31434690
pmcid: 6808530
Rigolet M, Hou C, Baba Amer Y, Aouizerate J, Periou B, Gherardi RK, et al. Distinct interferon signatures stratify inflammatory and dysimmune myopathies. RMD Open. 2019;5(1):e000811. https://doi.org/10.1136/rmdopen-2018-000811 .
doi: 10.1136/rmdopen-2018-000811
pubmed: 30886734
pmcid: 6397431
Goronzy JJ, Weyand CM. Mechanisms underlying T cell ageing. Nat Rev Immunol. 2019;19(9):573–83. https://doi.org/10.1038/s41577-019-0180-1 .
doi: 10.1038/s41577-019-0180-1
pubmed: 31186548
pmcid: 7584388
Naddaf E, Shelly S, Mandrekar J, Chamberlain AM, Hoffman EM, Ernste FC, Liewluck T. Survival and associated comorbidities in inclusion body myositis. Rheumatology (Oxford). 2022;61(5):2016–24. https://doi.org/10.1093/rheumatology/keab716 .
doi: 10.1093/rheumatology/keab716
pubmed: 34534271
Goyal NA, Coulis G, Duarte J, Farahat PK, Mannaa AH, Cauchii J, Irani T, et al. Immunophenotyping of inclusion body myositis blood T and NK cells. Neurology. 2022;98(13):e1374–83. https://doi.org/10.1212/WNL.0000000000200013 .
doi: 10.1212/WNL.0000000000200013
pubmed: 35131904
pmcid: 8967422
Eloranta ML, Barbasso Helmers S, Ulfgren AK, Ronnblom L, Alm GV, Lundberg IE. A possible mechanism for endogenous activation of the type I interferon system in myositis patients with anti-Jo-1 or anti-Ro 52/anti-Ro 60 autoantibodies. Arthritis Rheum. 2007;56(9):3112–24. https://doi.org/10.1002/art.22860 .
doi: 10.1002/art.22860
pubmed: 17763410
Jones EL, Laidlaw SM, Dustin LB. TRIM21/Ro52—roles in innate immunity and autoimmune disease. Front Immunol. 2021;12:738473. https://doi.org/10.3389/fimmu.2021.738473 .
doi: 10.3389/fimmu.2021.738473
pubmed: 34552597
pmcid: 8450407
Pinal-Fernandez I, Casal-Dominguez M, Derfoul A, Pak K, Miller FW, Milisenda JC, Grau-Junyent JM. Machine learning algorithms reveal unique gene expression profiles in muscle biopsies from patients with different types of myositis. Ann Rheum Dis. 2020;79(9):1234–42. https://doi.org/10.1136/annrheumdis-2019-216599 .
doi: 10.1136/annrheumdis-2019-216599
pubmed: 32546599
Cai Y, Zhu Y, Zheng J, Zhang Y, Chen W. NBR1 mediates autophagic degradation of IRF3 to negatively regulate type I interferon production. Biochem Biophys Res Commun. 2022;623:140–7. https://doi.org/10.1016/j.bbrc.2022.07.043 .
doi: 10.1016/j.bbrc.2022.07.043
pubmed: 35914352
D’Agostino C, Nogalska A, Cacciottolo M, Engel WK, Askanas V. Abnormalities of NBR1, a novel autophagy-associated protein, in muscle fibers of sporadic inclusion-body myositis. Acta Neuropathol. 2011;122(5):627–36. https://doi.org/10.1007/s00401-011-0874-3 .
doi: 10.1007/s00401-011-0874-3
pubmed: 21935636
Yamashita S, Matsuo Y, Tawara N, Hara K, Yamamoto M, Nishikami T, Kawakami K, et al. CYLD dysregulation in pathogenesis of sporadic inclusion body myositis. Sci Rep. 2019;9(1):11606. https://doi.org/10.1038/s41598-019-48115-2 .
doi: 10.1038/s41598-019-48115-2
pubmed: 31406156
pmcid: 6690995
Zhang Q, Jia Q, Gao W, Zhang W. The role of deubiquitinases in virus replication and host innate immune response. Front Microbiol. 2022;13:839624. https://doi.org/10.3389/fmicb.2022.839624 .
doi: 10.3389/fmicb.2022.839624
pubmed: 35283827
pmcid: 8908266
Gasset-Rosa F, Lu S, Yu H, Chen C, Melamed Z, Guo L, Shorter J, et al. Cytoplasmic TDP-43 de-mixing independent of stress granules drives inhibition of nuclear import, loss of nuclear TDP-43, and cell death. Neuron. 2019;102(2):339–57. https://doi.org/10.1016/j.neuron.2019.02.038 .
doi: 10.1016/j.neuron.2019.02.038
pubmed: 30853299
pmcid: 6548321
Adler BL, Christopher-Stine L. Triggers of inflammatory myopathy: insights into pathogenesis. Discov Med. 2018;25(136):75–83.
pubmed: 29579414
pmcid: 5921929
Singh H, Talapatra P, Arya S, Gupta V. Viral myositis as a close mimicker of polymyositis. Ann Trop Med Public Health. 2013;6:324–6. https://doi.org/10.4103/1755-6783.120997 .
doi: 10.4103/1755-6783.120997
Manzano GS, Woods JK, Amato AA. Covid-19-associated myopathy caused by type I interferonopathy. N Engl J Med. 2020;383(24):2389–90. https://doi.org/10.1056/NEJMc2031085 .
doi: 10.1056/NEJMc2031085
pubmed: 33216474
Uruha A, Noguchi S, Hayashi YK, Tsuburaya RS, Yonekawa T, Nonaka I, Nishino I. Hepatitis C virus infection in inclusion body myositis: a case-control study. Neurology. 2016;86(3):211–7. https://doi.org/10.1212/WNL.0000000000002291 .
doi: 10.1212/WNL.0000000000002291
pubmed: 26683644
Eura N. Anti-cytosolic 5’-nucleotidase 1A (cN1A) positivity in muscle is helpful in the diagnosis of sporadic inclusion body myositis: a study of 35 Japanese patients. J Neurol Neurosci. 2016. https://doi.org/10.3390/biomedicines11071963 .
doi: 10.3390/biomedicines11071963
Matsuura E, Umehara F, Nose H, Higuchi I, Matsuoka E, Izumi K, Kubota R, et al. Inclusion body myositis associated with human T-lymphotropic virus-type I infection: eleven patients from an endemic area in Japan. J Neuropathol Exp Neurol. 2008;67(1):41–9. https://doi.org/10.1097/nen.0b013e31815f38b7 .
doi: 10.1097/nen.0b013e31815f38b7
pubmed: 18091562
Ou SH, Wu F, Harrich D, García-Martínez LF, Gaynor RB. Cloning and characterization of a novel cellular protein, TDP-43, that binds to human immunodeficiency virus type 1 TAR DNA sequence motifs. J Virol. 1995;69(6):3584–96. https://doi.org/10.1128/JVI.69.6.3584-3596.1995 .
doi: 10.1128/JVI.69.6.3584-3596.1995
pubmed: 7745706
pmcid: 189073
Nehls J, Koppensteiner H, Brack-Werner R, Floss T, Schindler M. HIV-1 replication in human immune cells is independent of TAR DNA binding protein 43 (TDP-43) expression. PLoS ONE. 2014;9(8):e105478. https://doi.org/10.1371/journal.pone.0105478 .
doi: 10.1371/journal.pone.0105478
pubmed: 25127017
pmcid: 4134290
Zhou L, Miranda-Saksena M, Saksena NK. Viruses and neurodegeneration. Virol J. 2013;10:172. https://doi.org/10.1186/1743-422X-10-172 .
doi: 10.1186/1743-422X-10-172
pubmed: 23724961
pmcid: 3679988
Dalal F, Dalal H, McNew G. COVID-19-induced sporadic inclusion body myositis. Cureus. 2022;14(10):e30808. https://doi.org/10.7759/cureus.30808 .
doi: 10.7759/cureus.30808
pubmed: 36447724
pmcid: 9701533
Saud A, Naveen R, Aggarwal R, Gupta L. COVID-19 and myositis: what we know so far. Curr Rheumatol Rep. 2021;23(8):63. https://doi.org/10.1007/s11926-021-01023-9 .
doi: 10.1007/s11926-021-01023-9
pubmed: 34216297
pmcid: 8254439
Jacob S, Kapadia R, Soule T, Luo H, Schellenberg KL, Douville RN, Pfeffer G. Neuromuscular complications of SARS-CoV-2 and other viral infections. Front Neurol. 2022;13:914411. https://doi.org/10.3389/fneur.2022.914411 .
doi: 10.3389/fneur.2022.914411
pubmed: 35812094
pmcid: 9263266
Swartzman I, Gu JJ, Toner Z, Grover R, Suresh L, Ullman LE. Prevalence of myositis-specific autoantibodies and myositis-associated autoantibodies in COVID-19 patients: a pilot study and literature review. Cureus. 2022;14(9):e29752. https://doi.org/10.7759/cureus.29752 .
doi: 10.7759/cureus.29752
pubmed: 36324355
pmcid: 9617586
Holzer MT, Krusche M, Ruffer N, Haberstock H, Stephan M, Huber TB, Kotter I. New-onset dermatomyositis following SARS-CoV-2 infection and vaccination: a case-based review. Rheumatol Int. 2022;42(12):2267–76. https://doi.org/10.1007/s00296-022-05176-3 .
doi: 10.1007/s00296-022-05176-3
pubmed: 35939078
pmcid: 9358381
Huang C, Huang L, Wang Y, Li X, Ren L, Gu X, Kang L, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet. 2021;397(10270):220–32. https://doi.org/10.1016/S0140-6736(20)32656-8 .
doi: 10.1016/S0140-6736(20)32656-8
pubmed: 33428867
pmcid: 7833295
Su Y, Yuan D, Chen DG, Ng RH, Wang K, Choi J, Li S, et al. Multiple early factors anticipate post-acute COVID-19 sequelae. Cell. 2022;185(5):881–95. https://doi.org/10.1016/j.cell.2022.01.014 .
doi: 10.1016/j.cell.2022.01.014
pubmed: 35216672
pmcid: 8786632
Ramakrishnan RK, Kashour T, Hamid Q, Halwani R, Tleyjeh IM. Unraveling the mystery surrounding post-acute sequelae of COVID-19. Front Immunol. 2021;12:686029. https://doi.org/10.3389/fimmu.2021.686029 .
doi: 10.3389/fimmu.2021.686029
pubmed: 34276671
pmcid: 8278217
Jiang R, Roy B, Wu Q, Mohanty S, Nowak RJ, Shaw AC, Kleinstein SH, O’Connor KC. The plasma cell infiltrate populating the muscle tissue of patients with inclusion body myositis features distinct B cell receptor repertoire properties. Immunohorizons. 2023;7(5):310–22. https://doi.org/10.4049/immunohorizons.2200078 .
doi: 10.4049/immunohorizons.2200078
pubmed: 37171806
pmcid: 10579972
McLeish E, Sooda A, Slater N, Kachigunda B, Beer K, Paramalingam S, Lamont PJ, Chopra A, Mastaglia FL, Needham M, Coudert JD. Uncovering the significance of expanded CD8+ large granular lymphocytes in inclusion body myositis: Insights into T cell phenotype and functional alterations, and disease severity. Front Immunol. 2023;14:1153789. https://doi.org/10.3389/fimmu.2023.1153789 .
doi: 10.3389/fimmu.2023.1153789
pubmed: 37063893
pmcid: 10098158
Rose A, Isenalumhe L, Van den Bergh M, Sokol L. Clonal T-cell large granular lymphocytic disorders manifesting in patients with HIV-1 infection: case series and review of the literature. Mediterr J Hematol Infect Dis. 2018;10(1):e2018036. https://doi.org/10.4084/MJHID.2018.036 .
doi: 10.4084/MJHID.2018.036
pubmed: 30002792
pmcid: 6039084
Goronzy JJ, Li G, Yang Z, Weyand CM. The Janus head of T cell aging—autoimmunity and immunodeficiency. Front Immunol. 2013;4:131. https://doi.org/10.3389/fimmu.2013.00131 .
doi: 10.3389/fimmu.2013.00131
pubmed: 23761790
pmcid: 3671290
Rothwell S, Cooper RG, Lundberg IE, Gregersen PK, Hanna MG, Machado PM, Herbert MK, et al. Immune-array analysis in sporadic inclusion body myositis reveals HLA-DRB1 amino acid heterogeneity across the myositis spectrum. Arthritis Rheumatol. 2017;69(5):1090–9. https://doi.org/10.1002/art.40045 .
doi: 10.1002/art.40045
pubmed: 28086002
pmcid: 5516174
Rojana-Udomsart A, Bundell C, James I, Castley A, Martinez P, Christiansen F, Hollingsworth P, Mastaglia F. Frequency of autoantibodies and correlation with HLA-DRB1 genotype in sporadic inclusion body myositis (s-IBM): a population control study. J Neuroimmunol. 2012;249(1–2):66–70. https://doi.org/10.1016/j.jneuroim.2012.04.007 .
doi: 10.1016/j.jneuroim.2012.04.007
pubmed: 22554526
Slater N, Sooda A, McLeish E, Beer K, Brusch A, Shakya R, Bundell C, James I, Chopra A, Mastaglia FL, Needham M, Coudert JD. High-resolution HLA genotyping in inclusion body myositis refines 8.1 ancestral haplotype association to DRB1*03:01:01 and highlights pathogenic role of arginine-74 of DRβ1 chain. J Autoimmun. 2024;142:103150. https://doi.org/10.1016/j.jaut.2023.103150 .
doi: 10.1016/j.jaut.2023.103150
pubmed: 38043487
Miller FW, Lamb JA, Schmidt J, Nagaraju K. Risk factors and disease mechanisms in myositis. Nat Rev Rheumatol. 2018;14(5):255–68. https://doi.org/10.1038/nrrheum.2018.48 .
doi: 10.1038/nrrheum.2018.48
pubmed: 29674613
pmcid: 6745704
Ranasinghe S, Cutler S, Davis I, Lu R, Soghoian DZ, Qi Y, Sidney J, Kranias G, Flanders MD, Lindqvist M, Kuhl B, Alter G, Deeks SG, Walker BD, Gao X, Sette A, Carrington M, Streeck H. Association of HLA-DRB1-restricted CD4
doi: 10.1038/nm.3229
pubmed: 23793098
pmcid: 3974408
Barrett S, Ryan E, Crowe J. Association of the HLA-DRB1*01 allele with spontaneous viral clearance in an Irish cohort infected with hepatitis C virus via contaminated anti-D immunoglobulin. J Hepatol. 1999;30(6):979–83. https://doi.org/10.1016/s0168-8278(99)80249-9 .
doi: 10.1016/s0168-8278(99)80249-9
pubmed: 10406173
Bettencourt A, Carvalho C, Leal B, Brás S, Lopes D, Martins da Silva A, Santos E, et al. The protective role of HLA-DRB1(∗)13 in autoimmune diseases. J Immunol Res. 2015. https://doi.org/10.1155/2015/948723 .
doi: 10.1155/2015/948723
pubmed: 26605347
pmcid: 4641944
Ferre AL, Hunt PW, McConnell DH, Morris MM, Garcia JC, Pollard RB, Yee HF, et al. HIV controllers with HLA-DRB1*13 and HLA-DQB1*06 alleles have strong, polyfunctional mucosal CD4+ T-cell responses. J Virol. 2010;84(21):11020–9. https://doi.org/10.1128/JVI.00980-10 .
doi: 10.1128/JVI.00980-10
pubmed: 20719952
pmcid: 2953185
Kummee P, Tangkijvanich P, Poovorawan Y, Hirankarn N. Association of HLA-DRB1*13 and TNF-alpha gene polymorphisms with clearance of chronic hepatitis B infection and risk of hepatocellular carcinoma in Thai population. J Viral Hepat. 2007;14(12):841–8. https://doi.org/10.1111/j.1365-2893.2007.00880.x .
doi: 10.1111/j.1365-2893.2007.00880.x
pubmed: 18070287
James LM, Christova P, Lewis SM, Engdahl BE, Georgopoulos A, Georgopoulos AP. Protective effect of human leukocyte antigen (HLA) allele DRB1*13:02 on age-related brain gray matter volume reduction in healthy women. EBioMedicine. 2018;29:31–7. https://doi.org/10.1016/j.ebiom.2018.02.005 .
doi: 10.1016/j.ebiom.2018.02.005
pubmed: 29452862
pmcid: 5925575
Chikata T, Paes W, Kuse N, Partridge T, Gatanaga H, Zhang Y, Kuroki K, Maenaka K, Ternette N, Oka S, Borrow P, Takiguchi M. Impact of micropolymorphism outside the peptide binding groove in the clinically relevant allele HLA-C*14 on T cell responses in HIV-1 infection. J Virol. 2022;96(10):e0043222. https://doi.org/10.1128/jvi.00432-22 .
doi: 10.1128/jvi.00432-22
pubmed: 35475667
Zeng L, Chen K, Xiao F, Zhu CY, Bai JY, Tan S, Long L, et al. Potential common molecular mechanisms between Sjögren syndrome and inclusion body myositis: a bioinformatic analysis and in vivo validation. Front Immunol. 2023;14:1161476. https://doi.org/10.3389/fimmu.2023.1161476 .
doi: 10.3389/fimmu.2023.1161476
pubmed: 37153570
pmcid: 10160489
Lin A, Yan WH. The emerging roles of human leukocyte antigen-F in immune modulation and viral infection. Front Immunol. 2019;10:964. https://doi.org/10.3389/fimmu.2019.00964 .
doi: 10.3389/fimmu.2019.00964
pubmed: 31134067
pmcid: 6524545
Zhang J, Khasanova E, Zhang L. Bioinformatics analysis of gene expression profiles of Inclusion body myositis. Scand J Immunol. 2020;91(6):e12887. https://doi.org/10.1111/sji.12887 .
doi: 10.1111/sji.12887
pubmed: 32259312
Jasinska AJ, Pandrea I, Apetrei C. CCR5 as a coreceptor for human immunodeficiency virus and simian immunodeficiency viruses: a prototypic love-hate affair. Front Immunol. 2022;13:835994. https://doi.org/10.3389/fimmu.2022.835994 .
doi: 10.3389/fimmu.2022.835994
pubmed: 35154162
pmcid: 8829453
Ellwanger JH, Kulmann-Leal B, Kaminski VL, Rodrigues AG, Bragatte MAS, Chies JAB. Beyond HIV infection: neglected and varied impacts of CCR5 and CCR5Δ32 on viral diseases. Virus Res. 2020;286:198040. https://doi.org/10.1016/j.virusres.2020.198040 .
doi: 10.1016/j.virusres.2020.198040
pubmed: 32479976
Roos A, Preusse C, Hathazi D, Goebel HH, Stenzel W. Proteomic profiling unravels a key role of specific macrophage subtypes in sporadic inclusion body myositis. Front Immunol. 2019;10:1040. https://doi.org/10.3389/fimmu.2019.01040 .
doi: 10.3389/fimmu.2019.01040
pubmed: 31143183
pmcid: 6522546
Trifone C, Salido J, Ruiz MJ, Leng L, Quiroga MF, Salomón H, Bucala R, et al. Interaction between macrophage migration inhibitory factor and CD74 in human immunodeficiency virus type I infected primary monocyte-derived macrophages triggers the production of proinflammatory mediators and enhances infection of unactivated CD4+ T cells. Front Immunol. 2018;9:1494. https://doi.org/10.3389/fimmu.2018.01494 .
doi: 10.3389/fimmu.2018.01494
pubmed: 29997630
pmcid: 6030361
Connolly CM, Plomp L, Paik JJ, Allenbach Y. Possible future avenues for myositis therapeutics: DM, IMNM and IBM. Best Pract Res Clin Rheumatol. 2022;36(2):101762. https://doi.org/10.1016/j.berh.2022.101762 .
doi: 10.1016/j.berh.2022.101762
pubmed: 35778272
Astorga-Gamaza A, Perea D, Sanchez-Gaona N, Calvet-Mirabent M, Gallego-Cortés A, Grau-Expósito J, Sanchez-Cerrillo I, Rey J, Castellví J, Curran A, Burgos J, Navarro J, Suanzes P, Falcó V, Genescà M, Martín-Gayo E, Buzon MJ. KLRG1 expression on natural killer cells is associated with HIV persistence, and its targeting promotes the reduction of the viral reservoir. Cell Rep Med. 2023;4(10):101202. https://doi.org/10.1016/j.xcrm.2023.101202 .
doi: 10.1016/j.xcrm.2023.101202
pubmed: 37741278
pmcid: 10591043
Yu CH, Davidson S, Harapas CR, Hilton JB, Mlodzianoski MJ, Laohamonthonkul P, Louis C, et al. TDP-43 triggers mitochondrial DNA release via mPTP to activate cGAS/STING in ALS. Cell. 2020;183(3):636–49. https://doi.org/10.1016/j.cell.2020.09.020 .
doi: 10.1016/j.cell.2020.09.020
pubmed: 33031745
pmcid: 7599077
Mori F, Tada M, Kon T, Miki Y, Tanji K, Kurotaki H, Tomiyama M, et al. Phosphorylated TDP-43 aggregates in skeletal and cardiac muscle are a marker of myogenic degeneration in amyotrophic lateral sclerosis and various conditions. Acta Neuropathol Commun. 2019;7(1):165. https://doi.org/10.1186/s40478-019-0824-1 .
doi: 10.1186/s40478-019-0824-1
pubmed: 31661037
pmcid: 6816170
Damian L, Login CC, Solomon C, Belizna C, Encica S, Urian L, Jurcut C, et al. Inclusion body myositis and neoplasia: a narrative review. Int J Mol Sci. 2022;23(13):7358. https://doi.org/10.3390/ijms23137358 .
doi: 10.3390/ijms23137358
pubmed: 35806366
pmcid: 9266341
Pozzi S, Codron P, Soucy G, Renaud L, Cordeau PJ, Dutta K, Bareil C, Julien JP. Monoclonal full-length antibody against TAR DNA binding protein 43 reduces related proteinopathy in neurons. JCI Insight. 2020;5(21):e140420. https://doi.org/10.1172/jci.insight.140420 .
doi: 10.1172/jci.insight.140420
pubmed: 33021970
pmcid: 7710295
Wang P, Deng J, Dong J, Liu J, Bigio EH, Mesulam M, Wang T, et al. TDP-43 induces mitochondrial damage and activates the mitochondrial unfolded protein response. PLoS Genet. 2019;15(5):e1007947. https://doi.org/10.1371/journal.pgen.1007947 .
doi: 10.1371/journal.pgen.1007947
pubmed: 31100073
pmcid: 6524796
Njomen E, Tepe JJ. Proteasome activation as a new therapeutic approach to target proteotoxic disorders. J Med Chem. 2019;62(14):6469–81. https://doi.org/10.1021/acs.jmedchem.9b00101 .
doi: 10.1021/acs.jmedchem.9b00101
pubmed: 30839208
pmcid: 6745699
Moghadam-Kia S, Oddis CV. Current and new targets for treating myositis. Curr Opin Pharmacol. 2022;65:102257. https://doi.org/10.1016/j.coph.2022.102257 .
doi: 10.1016/j.coph.2022.102257
pubmed: 35724455
Guglielmi V, Cheli M, Tonin P, Vattemi G. Sporadic inclusion body myositis at the crossroads between muscle degeneration, inflammation, and aging. Int J Mol Sci. 2024;25(5):2742. https://doi.org/10.3390/ijms25052742 .
doi: 10.3390/ijms25052742
pubmed: 38473988
pmcid: 10932328
Terracciano C, Nogalska A, Engel WK, Askanas V. In AbetaPP-overexpressing cultured human muscle fibers proteasome inhibition enhances phosphorylation of AbetaPP751 and GSK3beta activation: effects mitigated by lithium and apparently relevant to sporadic inclusion-body myositis. J Neurochem. 2010;112(2):389–96.
doi: 10.1111/j.1471-4159.2009.06461.x
pubmed: 19878439
Hong N, Park JS, Kim HJ. Synapto-protective effect of lithium on HIV-1 Tat-induced synapse loss in rat hippocampal cultures. Anim Cells Syst (Seoul). 2021;26(1):1–9. https://doi.org/10.1080/19768354.2021.2018044 .
doi: 10.1080/19768354.2021.2018044
pubmed: 35308128
Schifitto G, Zhong J, Gill D, Peterson DR, Gaugh MD, Zhu T, Tivarus M, Cruttenden K, Maggirwar SB, Gendelman HE, Dewhurst S, Gelbard HA. Lithium therapy for human immunodeficiency virus type 1-associated neurocognitive impairment. J Neurovirol. 2009;15(2):176–86. https://doi.org/10.1080/13550280902758973 .
doi: 10.1080/13550280902758973
pubmed: 19306230
pmcid: 2747099